Cargando…

Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease

INTRODUCTION: Noninvasive tests, such as Fibrosis-4 (FIB-4), liver-stiffness measurement (LSM) by vibration-controlled transient elastography, and Fibroscan-AST (FAST), are frequently used for risk stratification in NAFLD. The comparative performance of FIB-4 and LSM and FAST to predict clinical out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Yu Jun, Urias, Esteban, Song, Michael W., Goyal, Tanvi, Tay, Wei Xuan, Han, Nicole Xinrong, Loo, Jing Hong, Qiu, Tian Yu, Wijarnpreecha, Karn, Chan, Yiong Huak, Chen, Vincent L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519529/ https://www.ncbi.nlm.nih.gov/pubmed/37738409 http://dx.doi.org/10.1097/HC9.0000000000000244

Ejemplares similares

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease
por: Fallatah, Hind I., et al.
Publicado: (2016)

Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy
por: Malekzadeh, Reza, et al.
Publicado: (2011)

Body fat distribution: a crucial target for intervention in nonalcoholic fatty liver disease and fibrosis
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
por: Wijarnpreecha, Karn, et al.
Publicado: (2021)

Update of liver fibrosis and steatosis with transient elastography (Fibroscan)
por: Wong, Grace Lai-Hung
Publicado: (2013)

Modest alcohol consumption and risk of advanced liver fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis
por: Wijarnpreecha, Karn, et al.
Publicado: (2021)

Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
por: Bertot, Luis C., et al.
Publicado: (2023)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis
por: Wijarnpreecha, Karn, et al.
Publicado: (2018)

Quantitative Evaluation of Liver Fibrosis on T1 Relaxometry in Comparison with Fibroscan
Publicado: (2020)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease
por: Ng, Ying Zhuang, et al.
Publicado: (2021)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Types of Physical Activity in Nonalcoholic Fatty Liver Disease and All-Cause and Cardiovascular Mortality
por: Kim, Donghee, et al.
Publicado: (2023)

Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis
por: Wijarnpreecha, Karn, et al.
Publicado: (2017)

AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
por: Moosavy, Seyed Hamid, et al.
Publicado: (2023)

Liver Hemangioma Might Lead to overestimation of Liver Fibrosis by Fibroscan; A Missed Issue in Two Cases
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2012)

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
por: Eris, Tansu, et al.
Publicado: (2023)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Amernia, Behnaz, et al.
Publicado: (2021)

Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age
por: Miller, Matthew J., et al.
Publicado: (2023)

Association between cardiac conduction defect and nonalcoholic fatty liver disease: a systematic review and meta-analysis
por: Wijarnpreecha, Karn, et al.
Publicado: (2020)

Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B
por: HUANG, RENGANG, et al.
Publicado: (2016)

Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis
por: Kim, Seung Up, et al.
Publicado: (2012)

Laboratory Tests, Liver Vessels Color Doppler Sonography, and FibroScan Findings in Patients with Nonalcoholic Fatty Liver Disease: An Observation Study
por: Alizadeh, Ahmad, et al.
Publicado: (2018)

Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial
por: Lim, Su Lin, et al.
Publicado: (2020)

Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease
por: Xu, Nan, et al.
Publicado: (2020)

Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients
por: Durango, Esteban, et al.
Publicado: (2013)

Correlation between Serum Ferritin Levels and Liver Stiffness measured by Fibroscan in patients with Chronic Hepatitis C
por: Latif, Saba, et al.
Publicado: (2020)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Can We Accurately Assess Liver Fibrosis with Fibroscan® Using Fewer Valid Measurements?
por: Pournik, Omid, et al.
Publicado: (2013)

Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection
por: Huang, Ling-Ling, et al.
Publicado: (2021)

Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India
por: Pathik, Parikh, et al.
Publicado: (2015)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hcu3fbl48rqntqjv0hdqpim165